CRTH2 Receptor Antagonist Response Genetic Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current asthma treatments with CRTH2 receptor antagonists show variable therapeutic effects among patients, necessitating a method to identify individuals who would benefit most from these therapies to enhance treatment efficacy and cost-effectiveness.
Innovation Solution
Identification of specific genetic polymorphisms, such as the C/T polymorphism at rs12748961, and other SNPs on human chromosome 1, which are associated with improved responses to CRTH2 receptor antagonist therapy, allowing for personalized treatment approaches by testing patients for these markers before administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CRTH2 receptor antagonist therapy is administered to all asthma patients, then some patients may experience therapeutic benefit, but treatment efficacy varies widely among patients due to lack of patient selection
Solution Approach 1:
The patent applies preliminary action by performing genetic testing for CRTH2 receptor polymorphisms before administering CRTH2 antagonist therapy. This advance identification of patients with responsive genotypes (e.g., those with minor alleles at rs12748961, rs12118655, rs6679073) allows clinicians to pre-select patients who are likely to benefit from the therapy, thereby improving treatment efficacy while avoiding unnecessary treatment of non-responsive patients.
2Reliability
If genetic testing for CRTH2 antagonist response markers is performed, then patient selection for therapy can be optimized, but additional testing steps and complexity are introduced
Solution Approach 1:
The patent replaces complex clinical trial methodologies and empirical patient selection approaches with a genetic biomarker-based selection system. By identifying specific CRTH2 receptor polymorphisms (such as rs12748961, rs12118655, rs6679073) that predict treatment response, the invention substitutes objective genetic testing for subjective clinical assessment, thereby improving reliability while actually simplifying the patient selection process through standardized genetic markers.
3Adaptability or versatility
If CRTH2 receptor antagonists are used as alternative oral therapy, then treatment options are expanded for patients not controlled on standard therapy, but compliance and effectiveness remain problematic
Solution Approach 1:
The patent applies local quality by tailoring the treatment approach to specific patient subgroups based on their genetic characteristics. Rather than applying CRTH2 antagonist therapy universally or as a blanket alternative, the invention identifies patients with specific CRTH2 polymorphism profiles (e.g., carrying responsive alleles at rs12748961, rs12118655, or rs6679073) who are most likely to respond. This personalized approach improves both compliance and effectiveness by ensuring that oral CRTH2 antagonist therapy is directed at patients who will genuinely benefit from it.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides genetic markers on human chromosome 1 that are associated with a beneficial response to CRTH2 receptor antagonists. These CRTH2 receptor antagonist response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with CRTH2 receptor antagonist compositions and drug products, in methods of treating patients having a disease susceptible to treatment with a CRTH2 receptor antagonist, and in methods for selecting the most appropriate therapy for such patients.